[Future antiviral therapy for chronic hepatitis C].
Tanaka
Katsuaki
K
Gastroenterological Center, Yokohama City University Medical Center.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000547:Amantadine / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D003546:Cysteine Endopeptidases; D012321:DNA-Directed RNA Polymerases / Q000037:antagonists & inhibitors; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D016174:Hepacivirus / Q000201:enzymology / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors; D007116:Immunization, Passive; D007372:Interferons / Q000627:therapeutic use; D009705:Nucleosides / Q000627:therapeutic use; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D020365:RNA Helicases / Q000037:antagonists & inhibitors; D000077596:Thymalfasin; D013947:Thymosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014761:Viral Hepatitis Vaccines / Q000627:therapeutic use; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases
D000276:Adjuvants, Immunologic; D000547:Amantadine; D000998:Antiviral Agents; D003546:Cysteine Endopeptidases; D012321:DNA-Directed RNA Polymerases; D004791:Enzyme Inhibitors; D007168:IMP Dehydrogenase; D007372:Interferons; D009705:Nucleosides; D016376:Oligonucleotides, Antisense; D020365:RNA Helicases; D000077596:Thymalfasin; D013947:Thymosin; D014761:Viral Hepatitis Vaccines; D017361:Viral Nonstructural Proteins; C084422:NS3 protein, hepatitis C virus; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases; C107824:NS2-3 protease